文献速递脊柱脊髓外科神经肿瘤

良性脊柱肿瘤的立体定向体部放疗:剂量递减是否合适?

Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate?
PubMed 文献 · J Neurosurg Spine · 2018-05-25

该研究基于2004至2016年38例患者共47个良性原发性脊柱肿瘤,比较低剂量与高剂量立体定向体部放疗(SBRT)的疗效。中位随访54个月,5年局部控制率76%,低剂量组73%与高剂量组83%无显著差异(p=0.52),未观察到3级及以上毒性。

要点

  • 低剂量(BED10Gy≤30)与高剂量SBRT的5年局部控制率分别为73%和83%,无显著差异(p=0.52)。
  • 倾向性评分校正的多变量分析显示两组局部控制无差异(HR 0.30,95%CI 0.02-5.40;p=0.41)。
  • 6例(16%)患者出现疼痛 flare,未发现显著预测因素;无3级及以上急性或晚期并发症。

核心结论

  • 对良性脊柱病变行SBRT的长期随访显示,低剂量(BED10Gy≤30)与高剂量SBRT在局部控制、疼痛 flare 率和长期毒性方面无显著差异。

研究设计与样本

  • 研究为前瞻性维持的机构放射外科数据库中2004至2016年接受 definitive SBRT 的38例患者共47个良性原发性脊柱肿瘤。
  • SBRT采用9-21 Gy分1-3次,使用CyberKnife(n=11[23%])、Synergy S(n=21[45%])或TrueBeam(n=15[32%])放射外科平台。
  • 以生物学有效剂量(BED10Gy)30 Gy为界将患者分为低剂量组和高剂量组。
  • 采用Kaplan-Meier法计算肿瘤控制率,log-rank法比较组间差异,并基于SBRT剂量选择的条件概率进行倾向性评分分析。

主要发现

  • 38例患者中最常见的组织学类型为脑膜瘤(15例)、神经鞘瘤(13例)和血管母细胞瘤(7例)。
  • SBRT时中位年龄58岁(范围25-91岁);47个治疗病灶位于颈椎(n=18)、胸椎(n=19)和腰骶椎(n=10)。
  • 5个(11%)病灶在SBRT后失访;剩余42个病灶的中位随访时间为54个月(范围1.2-133个月)。
  • 6例(16%)患者(共8个病灶)在SBRT后出现疼痛 flare,未发现疼痛 flare 的显著预测因素;无3级及以上急性或晚期并发症。
  • 5年局部控制率为76%(95%CI 61%-91%);低剂量组和高剂量组的5年局部控制率分别为73%(95%CI 53%-93%)和83%(95%CI 61%-100%)(p=0.52)。

关键数值与推荐

  • 低剂量与高剂量SBRT的5年局部控制率分别为73%(95%CI 53%-93%)和83%(95%CI 61%-100%)(p=0.52)。
  • 倾向性评分校正的多变量分析显示两组局部控制无差异(HR 0.30,95%CI 0.02-5.40;p=0.41)。
  • 5年局部控制率为76%(95%CI 61%-91%)。
  • 6例(16%)患者(共8个病灶)出现疼痛 flare;无3级及以上急性或晚期并发症。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE Akin to the nonoperative management of benign intracranial tumors, stereotactic body radiation therapy (SBRT) has emerged as a nonoperative treatment option for noninfiltrative primary spine tumors such as meningioma and schwannoma. The majority of initial series used higher doses of 16-24 Gy in 1-3 fractions. The authors hypothesized that lower doses (such as 12-13 Gy in 1 fraction) might provide an efficacy similar to that found with the dose de-escalation commonly used for intracranial radiosurgery to treat acoustic neuroma or meningioma and with a lower risk of toxicity. METHODS The authors identified 38 patients in a prospectively maintained institutional radiosurgery database who were treated with definitive SBRT for a total of 47 benign primary spine tumors between 2004 and 2016. SBRT consisted of 9-21 Gy in 1-3 fractions using the CyberKnife (n = 11 [23%]), Synergy S (n = 21 [45%]), or TrueBeam (n = 15 [32%]) radiosurgery platform. For a comparison of SBRT doses, patients were dichotomized into 1 of 2 groups (low-dose or high-dose SBRT) using a cutoff biologically effective dose (BED10Gy) of 30 Gy. Tumor control was calculated from the date of SBRT to the last follow-up using Kaplan-Meier survival analysis, with comparisons between groups completed using a log-rank method. To account for potential indication bias, a propensity score analysis was completed based on the conditional probabilities of SBRT dose selection. Toxicity was graded using Common Terminology Criteria for Adverse Events version 4.0 with a focus on grade 3+ toxicity and the incidence of pain flare. RESULTS For the 38 patients, the most common histological findings were meningioma (15 patients), schwannoma (13 patients), and hemangioblastoma (7 patients). The median age at SBRT was 58 years (range 25-91 years). The 47 treated lesions were located in the cervical (n = 18), thoracic (n = 19), or lumbosacral (n = 10) spine. Five (11%) lesions were lost to follow-up after SBRT. The median follow-up duration for the remaining 42 lesions was 54 months (range 1.2-133 months). Six (16%) patients (with a total of 8 lesions) experienced pain flare after SBRT; no significant predictor of pain flare was identified. No grade 3+ acute- or late-onset complication was noted. The 5-year local control rate was 76% (95% CI 61%-91%). No significant difference in local control according to dose, fractionation, previous radiation, surgery, tumor histology, age, treatment platform, planning target volume, or spine level treated was found. The 5-year local control rates for low- and high-dose treatments were 73% (95% CI 53%-93%) and 83% (95% CI 61%-100%) (p = 0.52). In propensity score-adjusted multivariable analysis, no difference in local control was identified (HR 0.30, 95% CI 0.02-5.40; p = 0.41). CONCLUSIONS Long-term follow-up of patients treated with SBRT for benign spinal lesions revealed no significant difference between low-dose (BED10Gy ≤ 30) and high-dose SBRT in local control, pain-flare rate, or long-term toxicity.

来源:J Neurosurg Spine,查看原文。版权归原作者所有。

引用

  1. Kalash R, Glaser SM, Flickinger JC, et al. Stereotactic body radiation therapy for benign spine tumors: is dose de-escalation appropriate? J Neurosurg Spine. 2018. PMID: 29799334. doi:10.3171/2017.12.SPINE17920

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。